120 related articles for article (PubMed ID: 34114922)
1. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
Komrokji R; Al Ali N; Padron E; Lancet J; Nazha A; Steensma D; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Sallman D
Leuk Lymphoma; 2021 Nov; 62(11):2762-2767. PubMed ID: 34114922
[TBL] [Abstract][Full Text] [Related]
2. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
Wang R; Xu Y; Wang B; Wang H; Wang M; Jing Y; Gao X; Yu L
Ann Hematol; 2024 Jan; 103(1):61-71. PubMed ID: 37926751
[TBL] [Abstract][Full Text] [Related]
3. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study
Davidoff AJ; Hu X; Bewersdorf JP; Wang R; Podoltsev NA; Huntington SF; Gore SD; Ma X; Zeidan AM
Leuk Lymphoma; 2020 May; 61(5):1178-1187. PubMed ID: 31878809
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.
Uy N; Singh A; Gore SD; Prebet T
Expert Opin Pharmacother; 2017 Aug; 18(12):1213-1224. PubMed ID: 28675065
[TBL] [Abstract][Full Text] [Related]
5. Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard-dose azacitidine.
Ogawa S; Sakamoto T; Matsuoka R; Ishitsuka K; Ogino Y; Sootome A; Makishima K; Yoshida C; Ito Y; Shimizu S; Suyama T; Shinagawa A; Ito T; Obara N; Kusakabe M; Sakata-Yanagimoto M; Miyazaki Y; Nannya Y; Chiba S
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1938. PubMed ID: 38014499
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Bazinet A; Desikan SP; Li Z; Rodriguez-Sevilla JJ; Venugopal S; Urrutia S; Montalban-Bravo G; Sasaki K; Chien KS; Hammond D; Kanagal-Shamanna R; Ganan-Gomez I; Kadia TM; Borthakur G; DiNardo CD; Daver NG; Jabbour EJ; Ravandi F; Kantarjian H; Garcia-Manero G
Clin Cancer Res; 2024 Apr; 30(7):1319-1326. PubMed ID: 38300723
[TBL] [Abstract][Full Text] [Related]
7. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roué G; Valcárcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellström-Lindberg E; Solé F; Esteller M
Cancer Res Commun; 2024 Feb; 4(2):365-377. PubMed ID: 38300528
[TBL] [Abstract][Full Text] [Related]
8. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.
Shallis RM; Zeidan AM
BMC Hematol; 2018; 18():4. PubMed ID: 29435332
[TBL] [Abstract][Full Text] [Related]
9. [Treating high-risk myelodysplastic syndromes].
Adès L
Bull Cancer; 2023 Nov; 110(11):1162-1167. PubMed ID: 37407322
[TBL] [Abstract][Full Text] [Related]
10. Advances in the management of higher-risk myelodysplastic syndromes: future prospects.
Gener-Ricos G; Rodriguez-Sevilla JJ; Urrutia S; Bataller A; Bazinet A; Garcia-Manero G
Leuk Lymphoma; 2024 May; ():1-12. PubMed ID: 38712556
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices.
Egloff SA; Cao X; Lachs R; Martin C; Mattlin M; Fennell E; Rayburn D; Schlauch D; Kurbegov D; Ide S; Battiwalla M
Leuk Lymphoma; 2023 Dec; 64(13):2101-2112. PubMed ID: 37680012
[TBL] [Abstract][Full Text] [Related]
12. Management of myelodysplastic syndromes after failure of response to hypomethylating agents.
Gil-Perez A; Montalban-Bravo G
Ther Adv Hematol; 2019; 10():2040620719847059. PubMed ID: 31156799
[TBL] [Abstract][Full Text] [Related]
13. A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm.
Dong A; Pan X; Lin CW; Huang YW; Krause H; Pan P; Baim A; Thomas MJ; Chen X; Yu J; Michaelis L; Liu P; Wang LS; Atallah E
J Cancer Prev; 2022 Jun; 27(2):129-138. PubMed ID: 35864858
[TBL] [Abstract][Full Text] [Related]
14. Analyzing Blood Cells of High-Risk Myelodysplastic Syndrome Patients Using Interferometric Phase Microscopy and Fluorescent Flow Cytometry.
Barnea I; Luria L; Girsault A; Dabah O; Dudaie M; Mirsky SK; Merkel D; Shaked NT
Bioengineering (Basel); 2024 Mar; 11(3):. PubMed ID: 38534530
[TBL] [Abstract][Full Text] [Related]
15. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
Nazha A; Komrokji R; Meggendorfer M; Jia X; Radakovich N; Shreve J; Hilton CB; Nagata Y; Hamilton BK; Mukherjee S; Al Ali N; Walter W; Hutter S; Padron E; Sallman D; Kuzmanovic T; Kerr C; Adema V; Steensma DP; Dezern A; Roboz G; Garcia-Manero G; Erba H; Haferlach C; Maciejewski JP; Haferlach T; Sekeres MA
J Clin Oncol; 2021 Nov; 39(33):3737-3746. PubMed ID: 34406850
[TBL] [Abstract][Full Text] [Related]
16. British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes.
Killick SB; Wiseman DH; Quek L; Cargo C; Culligan D; Enright H; Green S; Ingram W; Jones GL; Kell J; Krishnamurthy P; Kulasekararaj A; Mills J; Mufti G; Payne EM; Raghavan M; Stanworth SJ; Sternberg A; Bowen D;
Br J Haematol; 2021 Jul; 194(2):282-293. PubMed ID: 34137023
[No Abstract] [Full Text] [Related]
17. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Yamamoto K; Shinagawa A; DiNardo CD; Pratz KW; Ishizawa K; Miyamoto T; Komatsu N; Nakashima Y; Yoshida C; Fukuhara N; Usuki K; Yamauchi T; Asada N; Asou N; Choi I; Miyazaki Y; Honda H; Okubo S; Kurokawa M; Zhou Y; Zha J; Potluri J; Matsumura I
Jpn J Clin Oncol; 2022 Jan; 52(1):29-38. PubMed ID: 34739075
[TBL] [Abstract][Full Text] [Related]
18. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.
Tanaka T; Morita K; Loghavi S; Wang F; Furudate K; Sasaki Y; Little L; Gumbs C; Matthews J; Daver N; Pemmaraju N; DiNardo CD; Sasaki K; Yilmaz M; Kadia TM; Ravandi F; Konopleva MY; Kantarjian HM; Champlin RE; Al-Atrash G; Garcia-Manero G; Wang SA; Futreal PA; Takahashi K
Blood; 2021 Nov; 138(18):1733-1739. PubMed ID: 34115096
[TBL] [Abstract][Full Text] [Related]
19. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.
Trowbridge JJ; Starczynowski DT
J Exp Med; 2021 Jul; 218(7):. PubMed ID: 34129017
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
Tawbi HA; Forsyth PA; Hodi FS; Algazi AP; Hamid O; Lao CD; Moschos SJ; Atkins MB; Lewis K; Postow MA; Thomas RP; Glaspy J; Jang S; Khushalani NI; Pavlick AC; Ernstoff MS; Reardon DA; Kudchadkar R; Tarhini A; Chung C; Ritchings C; Durani P; Askelson M; Puzanov I; Margolin KA
Lancet Oncol; 2021 Dec; 22(12):1692-1704. PubMed ID: 34774225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
